Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Plaque Psoriasis
Interventions: Clobex Spray; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Fort Gratiot, Michigan

Conditions: Plaque Psoriasis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more

Conditions: Plaque Psoriasis
Interventions: 122-0551; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Anaheim, California • San Diego, California • Austin, Texas

Conditions: Atopic Dermatitis (AD), Psoriasis (PsO)
Interventions: LPX-TI641, Placebo; Drug
Lead sponsor: LAPIX Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Fargo, North Dakota • Dallas, Texas

Conditions: Psoriasis, Aging, Epigenetic Disorder, Inflammation; Skin
Interventions: TILDRAKIZUMAB; Biological
Lead sponsor: Carlos Wambier; Other
Eligibility: 35 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Chronic Plaque Psoriasis
Interventions: Alefacept; Drug
Lead sponsor: Biogen; Industry
Eligibility: 16 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 19
States / cities: Irvine, California • San Francisco, California • Santa Monica, California + 15 more

Conditions: Psoriasis
Interventions: Enstilar 0.005%-0.064% Topical Foam; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Psoriasis, Pregnancy
Interventions: Not listed
Lead sponsor: Genentech, Inc.; Industry
Eligibility: Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Psoriasis (PsO), Psoriatic Arthritis (PsA)
Interventions: Aspirin, Clopidogrel, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 19
States / cities: Tucson, Arizona • Fountain Valley, California • La Mesa, California + 13 more

Conditions: Psoriatic Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 17
States / cities: Phoenix, Arizona • Colorado Springs, Colorado • Bridgeport, Connecticut + 14 more

Conditions: Scalp Psoriasis
Interventions: PART 1: Double-blind Placebo-controlled, PART 2: Double-blind Active Treatment Extension; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 19
States / cities: Encinitas, California • Fountain Valley, California • Fremont, California + 15 more

Conditions: Psoriasis
Interventions: Guselkumab, Midazolam, Warfarin, Omeprazole, Dextromethorphan, Caffeine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Anniston, Alabama • North Hollywood, California • Orlando, Florida + 5 more

Conditions: Psoriasis
Interventions: clobetasol propionate spray 0.05%, calcitriol ointment; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: San Diego, California • Newnan, Georgia • Snellville, Georgia + 9 more

Conditions: Psoriasis
Interventions: Acitretin 25Mg Oral Capsule, Excimer laser, Tazarotene 0.1% Gel,Top, Sham excimer laser; Drug · Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Plaque Psoriasis, Psoriasis
Interventions: M923, Humira; Biological
Lead sponsor: Momenta Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 24
States / cities: Beverly Hills, California • Encino, California • La Mesa, California + 20 more

Conditions: Atopic Dermatitis, Psoriasis, Healthy
Interventions: AD subject visit sampling procedures, PS subject visit sampling procedures, Healthy control visit sampling procedures; Other
Lead sponsor: University of Rochester; Other
Eligibility: 13 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Generalized Pustular Psoriasis
Interventions: Spesolimab, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Auburn Hills, Michigan • St Louis, Missouri

Conditions: Chronic Plaque Psoriasis
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 6,065 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2023
U.S. locations: 222
States / cities: Birmingham, Alabama • Daphne, Alabama • Huntsville, Alabama + 173 more

Conditions: Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Psoriatic Arthritis, Anxiety Disorders, Depressive Disorders, Moderate Depression, Moderate Anxiety
Interventions: Creating Health Online Course, Delayed access to Creating Health Online Course; Behavioral
Lead sponsor: Terry L. Wahls; Other
Eligibility: 18 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
Interventions: Tildrakizumab, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 11
States / cities: Encinitas, California • Fountain Valley, California • Los Angeles, California + 8 more

Conditions: Plaque Psoriasis
Interventions: M518101, placebo, Dovonex; Drug
Lead sponsor: Maruho Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 32
States / cities: Birmingham, Alabama • Mobile, Alabama • Fresno, California + 28 more

Conditions: Psoriasis
Interventions: Risankizumab, Ustekinumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Birmingham, Alabama • Fountain Valley, California • Sacramento, California + 18 more

Conditions: Psoriasis
Interventions: Alefacept exposure; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,897 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 241
States / cities: Birmingham, Alabama • Fairhope, Alabama • Gadsden, Alabama + 206 more

Search by objective public record fields.

Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

Effects of Tildrakizumab on Epigenetic Age

Safety and Tolerability of Repeat Courses of IM Alefacept

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)

A Clinical Trial of Antiplatelets in Psoriasis

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

Skin Microbial Ecology in Atopic Dermatitis

A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

Chronic Plaque Psoriasis (Ps) Registry

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Assessment and Tracking of Long-term Alefacept Safety